Spero Therapeutics (SPRO)
(Delayed Data from NSDQ)
$1.27 USD
-0.04 (-3.05%)
Updated Jul 8, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SPRO 1.27 -0.04(-3.05%)
Will SPRO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SPRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRO
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
SPRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?
Other News for SPRO
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics Expands Stock Incentive Plan for Growth
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
Buy Rating Affirmed for Spero Therapeutics Amidst Drug Pipeline Progress and Strategic Partnerships